A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Number of Participants Experiencing Adverse Events (AEs) - Part 1

  Measured over: From first dose up to 100 days after last dose (up to 65 months)

• Number of Participants Experiencing Serious Adverse Events (SAEs) - Part 1

  Measured over: From first dose up to 100 days after last dose (up to 65 months)

• Number of Participants Experiencing Dose Limiting Toxicities (DLTs) - Part 1

  Measured over: From first dose up to 100 days after last dose (up to 65 months)

• Number of Participants Experiencing Adverse Events (AEs) Leading to Discontinuation - Part 1

  Measured over: From first dose up to 100 days after last dose (up to 65 months)

• Number of Participants Who Died - Part 1

  Measured over: From first dose up to 100 days after last dose (up to 65 months)

• Most Frequently Reported Grade 3 and Grade 4 Laboratory Test Results - Part 1

  Measured over: From first dose up to 30 days after last dose (up to 63 months)

• Objective Response Rate (ORR) - Part 2

  Measured over: From the date of the first dose to the date of first objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurred first (up to approximately 22 months)

Changes Tremor has spotted